English
Specials
    Premium
    My Alerts
    MoneycontrolGo PRO @₹99
    Moneycontrol PRO
    Check Credit Score
    Check Credit Score
    HomeNewsBusiness

    Lupin gets USFDA nod for generic Tadalafil tablets

    The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version of Eli Lilly and Company's Adcirca tablets.

    PTI
    December 17, 2018 / 03:53 PM IST
    Lupin | Rakesh Jhunjhunwala increased stake in company to 1.53 percent in September quarter, from 1.47 percent in June quarter; LIC also raised stake to 3.71 percent from 2.7 percent and MFs to 12.58 percent from 11.94 percent. (Image: Reuters)

    Lupin | Rakesh Jhunjhunwala increased stake in company to 1.53 percent in September quarter, from 1.47 percent in June quarter; LIC also raised stake to 3.71 percent from 2.7 percent and MFs to 12.58 percent from 11.94 percent. (Image: Reuters)

     
     
    live
    • bselive
    • nselive
    Volume
    Todays L/H
    More

    Drug maker Lupin on Monday said it has received tentative approval from the US health regulator for Tadalafil tablets, used to treat erectile dysfunction and enlarged prostate, in the American market.

    The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version of Eli Lilly and Company's Adcirca tablets.

    According to IQVIA MAT September data, Adcirca tablets, 20 mg, had annual sales of around USD 503.8 million in the US.

    PTI
    Tags: #BSE #Business #Companies #Lupin #USFDA
    first published: Dec 17, 2018 03:45 pm

    Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347